Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by jdstoxon Jun 17, 2020 2:41pm
242 Views
Post# 31161454

xB3-001 & Chemobrain

xB3-001 & Chemobraindigitel, you should read what you copy/paste here.

I gave it a 10-minute look. The study was with trastuzumab (TZB) and atorvastatin (Lipitor) in a nude mouse model with HER2+ gastric cancer. It's recognized in the study that the chemobrain may be mouse model and receptor dependent. And Lipitor mitigated it. (That's the good news!) And in the study, TZB never entered the brain. And that there is a receptor involved that could be targeted as a mitigator.

Further, since TZM MAY have been involved, since the study was NOT about brain tumours, since the study was done with suspicious nude mice, but since TZM has been used for over 20 years with immense success, why are you being this irresponsible?

You have no idea what you're talking about, digitel, and you know why? Because copy/pasting isn't "learning," "thinking" or "talking" about anything. It's simply the movement of words around, without knowing what the words even are, let alone what they mean.

Read the paper before you post it!

There are profoundly compelling reasons why the PhDs and MDs at Bioasis are moving xB3-001 to the clinic. 

So, minedigger, how should I respond to such irresponsible behaviour as this?

Awe, gee, Mr. Digitel, I, ah, I really appreciate that you gave us your thoughts on this but maybe we should take a little look at so we, maybe, might know WTF we're talking about!
Bullboard Posts